New hope for early lung cancer: immunotherapy plus radiation trial launches
NCT ID NCT07379398
First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with precise radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the treatment. The goal is to see if the combination improves how long patients live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.